Taligen Therapeutics Adds $10 Mil. Tranche, Reveals Broad Patent
This article was originally published in The Pink Sheet Daily
Executive Summary
The developer of therapies that act on the complement system expects to partner in ophthalmology while keeping its orphan disease program in-house.
You may also be interested in...
Alexion Buys Taligen, Adding A Complement To Its Research Pipeline
Alexion acquired the privately-held biotech for $111 million plus milestone payments
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.